<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bao Y</submitter><funding>National Health and Medical Research Council</funding><pagination>29</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10276447</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Atrial fibrillation (AF) is a common cardiac complication during cancer treatment. It is unclear if cancer survivors have increased AF risk when compared to the population. AF screening is now recommended in patients ≥65 years, however there are no specific recommendations in the oncology population. We sought to compare the AF detection rate of cancer survivors compared to the general population.&lt;h4>Methods&lt;/h4>We searched the Pubmed, Embase and Web of Science databases using search terms related to AF and cancer mapped to subject headings. We included English language studies, limited to adults > 18 years who were > 12 months post completion of cancer treatment. Using a random-effects model we calculated the overall AF detection rate. Meta-regression analysis was perfo</pubmed_abstract><journal>Cardio-oncology (London, England)</journal><pubmed_title>Atrial fibrillation in cancer survivors - a systematic review and meta-analysis.</pubmed_title><pmcid>PMC10276447</pmcid><funding_grant_id>Investigator grant 2008129</funding_grant_id><pubmed_authors>Bao Y</pubmed_authors><pubmed_authors>Lee J</pubmed_authors><pubmed_authors>Ramkumar S</pubmed_authors><pubmed_authors>Thakur U</pubmed_authors><pubmed_authors>Marwick TH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Atrial fibrillation in cancer survivors - a systematic review and meta-analysis.</name><description>&lt;h4>Background&lt;/h4>Atrial fibrillation (AF) is a common cardiac complication during cancer treatment. It is unclear if cancer survivors have increased AF risk when compared to the population. AF screening is now recommended in patients ≥65 years, however there are no specific recommendations in the oncology population. We sought to compare the AF detection rate of cancer survivors compared to the general population.&lt;h4>Methods&lt;/h4>We searched the Pubmed, Embase and Web of Science databases using search terms related to AF and cancer mapped to subject headings. We included English language studies, limited to adults > 18 years who were > 12 months post completion of cancer treatment. Using a random-effects model we calculated the overall AF detection rate. Meta-regression analysis was perfo</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2025-05-29T19:19:02Z</modification><creation>2025-05-29T19:19:02Z</creation></dates><accession>S-EPMC10276447</accession><cross_references><pubmed>37330583</pubmed><doi>10.1186/s40959-023-00180-3</doi></cross_references></HashMap>